Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neladenoson Bialanate in HFrEF (PANTHEON)
NCT02992288Phase 2Completed
- Sponsor
- Bayer
- Start
- Feb 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of neladenoson bialanate in heart failure with reduced ejection fraction (HFrEF), sponsored by Bayer. Started Feb 2017; status: completed.
02
Drugs
neladenoson bialanate
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT02992288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992288.